Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system

ConclusionsOur results, although restricted, provide information to policymakers and health professionals that the use of a 52 mg LNG-IUS over a 5-year median did not increase disease activity or damage index scores among women with SLE, with and without APS.

http://link.springer.com/10.1007/s00404-019-05131-x

Source: Archives of Gynecology and Obstetrics - April 1, 2019 Category: OBGYN Source Type: research